Complexo Hospitalario Universitario A Coruña
Welcome,         Profile    Billing    Logout  
 1 Trial 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sullivan, Ivana
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Recruiting
3
756
Europe, US, RoW
Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab
Shanghai Junshi Bioscience Co., Ltd.
Limited-stage Small Cell Lung Cancer (LS-SCLC)
07/27
07/29
NADIM-ADJUVANT, NCT04564157: New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy

Active, not recruiting
3
210
Europe
Carboplatin, Paraplatin, Paclitaxel, Taxol, Nivolumab, Opdivo
Fundación GECP
Non-Small Cell Lung Cancer, Adjuvant Chemotherapy
04/30
04/31
BA3011-002, NCT04681131: CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

Recruiting
2
240
Europe, US, RoW
CAB-AXL-ADC, BA3011, PD-1 inhibitor
BioAtla, Inc.
Non-Small-Cell Lung Cancer
08/25
08/25
CHESS, NCT03965468: Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC

Recruiting
2
96
Europe
Durvalumab, Imfinzi, Carboplatin, Paclitaxel, Stereotactic body radiation therapy (SBRT), Surgical resection - definitive local treatment., Radical radiotherapy - definitive local treatment., Tremelimumab
ETOP IBCSG Partners Foundation, AstraZeneca
Non-small Cell Lung Cancer, Stage IV, Oligometastasis
08/26
12/26
APOLO, NCT04776447 / 2020-004459-33: Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy.

Recruiting
2
51
Europe
Carboplatin, Carboplatinum, Placlitaxel, Taxol, Atezolizumab, Tecentriq
Fundación GECP
Lung Diseases, Carcinoma, Non-Small-Cell Lung, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Respiratory Tract Neoplasms, Carcinoma Bronchiogenic Stage III, Thoracic Neoplasms
11/26
11/27
BOUNCE, NCT05718297: Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer

Recruiting
2
44
Europe
Brigatinib, Durvalumab
ETOP IBCSG Partners Foundation, Takeda
NSCLC, Stage III, ALK-rearrangement
04/27
04/29
BA3021-001, NCT03504488: CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Recruiting
1/2
420
Europe, US, RoW
CAB-ROR2-ADC, BA3021, PD-1 inhibitor
BioAtla, Inc.
Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
12/25
12/25
SPECTA, NCT02834884: Screening Cancer Patients for Efficient Clinical Trial Access

Recruiting
N/A
4975
Europe, RoW
RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon
European Organisation for Research and Treatment of Cancer - EORTC
All Tumor Types
03/26
03/26
Abal, Venancio Chantada
No trials found
Concepción, Victor Noriega
No trials found

Download Options